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Protective effect of 20-hydroxyeicosatetraenoic acid (20-
HETE) on glomerular protein permeability barrier.
Background. Proteinuria is a significant problem in medicine
today, although glomerular events underlying it are unknown.
Products of cytochrome P450 (CYP450) pathway of arachidonic
acid metabolism are increasingly recognized as playing major
roles in renal function. We used in vitro albumin permeabil-
ity (Palb) as a measure of injury and puromycin aminonucle-
oside (PAN) as an injurious agent to test the hypothesis that
20-hydroxyeicosatetraenoic acid (20-HETE) protects the
glomerular filtration barrier from increased Palb.
Methods. We determined Palb in the following experimental
groups: (1) isolated rat glomeruli incubated with PAN (5 lg/mL)
for 5, 15, 30 or 60 minutes; (2) isolated glomeruli preincu-
bated with 20-HETE (1.0 nmol/L to 100 nmol/L) for 15 min-
utes followed by additional incubation with PAN (5 lg/mL)
for 15 minutes; (3) isolated glomeruli from rats treated with
the CYP450 4A inducer clofibrate, and incubated with PAN
(5 lg/mL) for 15 minutes; and (4) appropriate controls for each
group. CYP450 4A levels were measured in glomeruli isolated
from rats treated with clofibrate or vehicle.
Results. PAN increased Palb of isolated glomeruli as early as
5 minutes (Palb 0.33 ± 0.21, P < 0.05 vs. control). Maximal effect
occurred at 30 minutes (Palb 0.75 ± 0.16, P < 0.001 vs. control).
Inclusion of 20-HETE (100 nmol/L) blocked the increased Palb
caused by PAN (Palb 0.05 ± 0.13). Likewise, glomeruli isolated
from rats treated with clofibrate were protected from PAN-
induced increase in Palb (Palb 0.19 ± 0.03). Treatment with clofi-
brate significantly increased glomerular CYP450 4A expression.
Conclusion. PAN directly and immediately affects the
glomerular permeability barrier. Furthermore, exogenous 20-
HETE or clofibrate treatment protects glomeruli from in-
creased Palb caused by PAN. Relative lack of 20-HETE may be
a general characteristic of proteinuric states. Conversely, mea-
sures used to treat and/or prevent proteinuria may act to restore
or increase glomerular 20-HETE levels.
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Proteinuria is one of the most important problems in
medicine today. The mechanisms and cellular events that
result in proteinuria are not understood, and treatment of
human disease is largely empiric. The mainstays of treat-
ment of nephrotic syndrome include corticosteroids, cy-
closporine A, and angiotensin-converting enzyme (ACE)
inhibitors, as well as lipid-lowering agents such as fibrates,
and maneuvers such as low salt diet [1]. Each of these in-
terventions has been shown in animal models to increase
renal expression and/or activity of cytochrome P450
4A (CYP450 4A), an enzyme that metabolizes arachi-
donic acid and other lipid mediators, and whose primary
product is 20-hydroxyeicosatetraenoic acid (20-HETE)
[2–11]. These observations lead us to hypothesize that
20-HETE plays an important role in the maintenance
of the glomerular protein permeability barrier, and that
20-HETE is protective against agents and/or conditions
that result in increased glomerular leak of protein.
The importance of 20-HETE in renal physiology is
being increasingly recognized. 20-HETE is the primary
eicosanoid synthesized by renal tissue, and causes vaso-
constriction, and mediates natriuresis and the effect of
parathyroid hormone (PTH) in renal tubules [12, 13]. The
effect of 20-HETE on glomerular function has not previ-
ously been described.
We use the glomerular epithelial cell toxin puromycin
aminonucleoside (PAN) in the reported studies. PAN-
induced nephrosis has long been used as an animal model
of human minimal change disease (MCD) and focal seg-
mental glomerulosclerosis (FSGS), and is used to study
mechanisms of proteinuria in general [14].
We report the direct and immediate effect of PAN on
the glomerular protein permeability barrier, as evidenced
by increased in vitro albumin permeability (Palb). More
important, we describe the protective effect of 20-HETE
on the glomerular protein permeability barrier.
METHODS
Kidneys from male Sprague-Dawley rats (180 to
250 g) were removed under halothane (Halocarbon,
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River Edge, NJ, USA) anesthesia. The Animal Care and
Use Committee at the Medical College of Wisconsin
approved all protocols. Glomeruli were isolated using
standard sieving techniques. For each experimental con-
dition, albumin permeability (Palb) was determined us-
ing volumetric change in response to an oncotic gradient
[15].
Treatment of glomeruli and rats
In preliminary experiments, we incubated glomeruli
with PAN 5 or 10 lg/mL (Sigma Chemical Co., St. Louis,
MO, USA). There was no difference in the effect on Palb
(data not shown), so we used PAN 5 lg/mL in subse-
quent studies. This concentration of PAN is consistent
with those shown by other investigators to have physio-
logic effects [16–18]. In order to determine if PAN has
a direct effect on the glomerular protein permeability
barrier, and the time course of such an effect, isolated
glomeruli were incubated with PAN (5 lg/mL) or saline
for 5 to 60 minutes at 37◦C.
To determine if 20-HETE, the major product of
CYP450 4A, altered the effect of PAN on glomeru-
lar function, isolated glomeruli were pre-incubated with
20-HETE (10 nmol/L to 100 nmol/L) (Cayman, Ann
Arbor, MI, USA) for 15 minutes at 37◦C followed by
incubation for additional 15 minutes after adding PAN
(5 lg/mL). Control glomeruli were incubated with saline.
These concentrations of 20-HETE were chosen as they
have been shown by other investigators to have physio-
logic effects in cell or tissue culture systems [19, 20].
To induce expression of CYP450 4A, rats were treated
with clofibrate (500 mg/kg/day, intraperitoneally) (Sigma
Chemical Co.) or vehicle (olive oil, 1 mL/kg/day, in-
traperitoneally) for 3 days. Glomeruli were isolated after
treatment and incubated with PAN (5 lg/mL) or saline
for 15 minutes at 37◦C.
Measurement of CYP450 expression
Glomeruli were isolated from rats treated with clofi-
brate or vehicle as described above. Western blot-
ting was carried out using 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
minigels (Bio-Rad, Hercules, CA, USA) and proteins
were electrotransferred to a nitrocelluslose membrane
(Amersham, Piscataway, NJ, USA). Membranes were
blocked with 2% fat free milk powder in Tris-buffered
saline with 0.1% Tween (TBST) followed by incubation
with rabbit anti-P450 4A polyclonal antibody (Abcam,
Cambridge, MA, USA). Horseradish peroxidase (HRP)-
conjugated goat antirabbit IgG (Sigma Chemical Co.) was
used as the secondary antibody. Enhanced chemilumines-
cence (ECL) reagent (Amersham) was used to develop
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Fig. 1. Puromycin aminonucleoside (PAN) increases Palb of isolated
glomeruli. Isolated glomeruli were incubated with PAN (5 lg/mL) for
various time periods, and Palb was measured. Values for Palb are ex-
pressed as mean ± SEM (N = number of glomeruli). ∗P < 0.05 vs.
control; ∗∗P < 0.01 vs. control; #P < 0.001 vs. control. Palb at 15 minutes
vs. 30 and 60 minutes = NS.
the chemiluminescence on BioMax x-ray film (Kodak,
Rochester, NY, USA).
Calculation of Palb
The volume response of glomerular capillaries to an
oncotic gradient was measured as follows [15]. Glomeruli
were observed using videomicroscopy before and af-
ter the induction of an oncotic gradient across the
glomerular capillary wall. This resulted in an increase
in glomerular capillary volume. The change in volume
(V) of each glomerulus was expressed as: V =
(Vfinal − Vinitial)/Vinitial × 100%. The reflection co-
efficient of albumin (ralb) was calculated as: ralb =
Vexperimental/Vcontrol. Convectional albumin perme-
ability (Palb) was defined as (1 − ralb) [15].
Statistical analysis
Palb values are expressed as mean ± SEM. N repre-
sents the number of glomeruli. Values of groups were
compared using analysis of variance (ANOVA) or paired
t test. Significance was defined as P < 0.05.
RESULTS
PAN increases Palb of isolated glomeruli
PAN (5 lg/mL) increased Palb of isolated glomeruli as
early as 5 minutes (Palb = 0.33 ± 0.21) (N = 8) (P < 0.05
vs. control) as shown in Figure 1. Maximal effect occurred
at 30 minutes (Palb = 0.75 ± 0.16) (N = 8) (P < 0.001 vs.
control). Palb was also increased at 15 minutes (Palb =
0.58 ± 0.15) (N = 15) (P < 0.01 vs. control) and 60 min-
utes (Palb = 0.63 ± 0.14) (N = 9) (P < 0.01 vs. control).
The difference between Palb at 15 and 30 minutes was
not significant; therefore, we used 15-minute incubation
period in subsequent experiments.
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Fig. 2. 20-hydroxyeicosatetraenoic acid (20-HETE) protects glomeru-
lar permeability barrier from increased Palb caused by puromycin
aminonucleoside (PAN). Isolated glomeruli were preincubated with
20-HETE (10 to 100 nmol/L) followed by further incubation for 15
minutes after adding PAN (5 lg/mL), and Palb was measured. Values
for Palb are expressed as mean ± SEM (N = number of glomeruli).
#P < 0.05 vs. PAN; ∗P < 0.02 vs. PAN.
20-HETE protects the glomerular protein permeability
barrier from the increased Palb caused by PAN
Palb of glomeruli incubated with 20-HETE
(100 nmol/L) in addition to PAN was not significantly
different from controls (Palb = 0.05 ± 0.13) (N = 5) as
shown in Figure 2. This protective effect of 20-HETE
was concentration dependent, and was evident at a con-
centration as low as 50 nmol/L. These concentrations of
20-HETE are similar to those previously shown to have
physiologic effect [19–21]. Incubation with 20-HETE
alone did not affect Palb (20-HETE 100 nmol/L Palb =
0.03 ± 0.06) (N = 10) (10 nmol/L Palb = 0.03 ± 0.05)
(N = 10) (data not shown).
Glomeruli from rats pretreated with clofibrate
were protected from PAN
Clofibrate is known to induce CYP450 4A, the major
source of 20-HETE, in kidney tissue [7–10]. Glomeruli
were isolated from rats pretreated with clofibrate for
3 days, then incubated with PAN (5 lg/mL) for 15 min-
utes. The effect of PAN on Palb of these glomeruli was
significantly less than on glomeruli from vehicle-treated
rats incubated with PAN [clofibrate 0.19 ± 0.03 (N = 15)
vs. vehicle 0.67 ± 0.05 (N = 15)] (P < 0.001) (Fig. 3). Treat-
ment with clofibrate or vehicle alone did not increase Palb
[Palb 0.003 ± 0.04 (N = 15) and 0.002 ± 0.07 (N = 15),
respectively]. These results suggest that altered enzyme
expression and consequent alteration in eicosanoid pro-
duction may confer protection from glomerular injury.
Clofibrate treatment increases glomerular expression
of CYP450 4A
Clofibrate and other fibrates have been shown to in-
duced CYP450 4A expression and/or activity in renal
tissue such as cortical or medullary microsomes [7, 9].
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Fig. 3. Glomeruli from rats treated with clofibrate are protected from
increased Palb caused by puromycin aminonucleoside (PAN). Rats were
treated with clofibrate (500 mg/kg/day, intraperitoneally) or vehicle
(olive oil, 1 mL/kg/day, intraperitoneally) for 3 days. Glomeruli were
isolated and incubated with PAN (5 lg/mL) or saline for 15 minutes. Val-
ues for Palb are expressed as mean ± SEM (N = number of glomeruli).∗P < 0.001 vs. control.
In order to verify our hypothesis that clofibrate alters
glomerular enzyme expression, glomeruli were isolated
from rats treated with clofibrate or vehicle for 3 days.
Glomerular levels of CYP450 4A were increased in rats
treated with clofibrate as compared to vehicle-treated
controls (Fig. 4).
DISCUSSION
Results of these studies can be summarized as follows.
PAN has a direct and immediate effect on the glomerular
protein permeability barrier, and increases Palb of iso-
lated glomeruli in an in vitro assay. 20-HETE protects
the glomerular permeability barrier from increased Palb
caused by PAN, while 20-HETE itself has no effect on
Palb. Glomeruli from rats pretreated with clofibrate are
likewise protected from the increased Palb caused by PAN
in vitro, and exhibit increased expression of CYP450 4A.
PAN induces heavy proteinuria when injected into rats
and is considered a glomerular epithelial cell toxin [22].
PAN nephrosis provides a model for human MCD and
FSGS, as well as for the study of fundamental processes
involved in proteinuria [14, 22, 23]. Generation of reac-
tive oxygen species (ROS), in particular superoxide, is a
major mechanism of glomerular injury in PAN nephro-
sis [24]. Our findings of immediate glomerular injury in-
duced by PAN agree with the observations by others that
glomerular events occur within minutes of exposure [24–
26]. The PAN-induced increase in Palb occurs immedi-
ately and precedes the development of proteinuria, which
occurs several days after injection [14].
Arachidonic acid metabolites (eicosanoids) play a piv-
otal role in control of glomerular function. Products
of cyclooxygenase are the best known, and impair the
glomerular protein permeability barrier in vitro [27].
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Fig. 4. Glomeruli from rats treated with
clofibrate show increased expression of cy-
tochrome P450 (CYP450 4A). Experimen-
tal rats were treated with clofibrate (500
mg/kg/day, intraperitoneally) and control rats
with vehicle (olive oil, 1 mL/kg/day, intraperi-
toneally) for 3 days. Isolated glomeruli were
homogenized in a lysis buffer. P450 4A expres-
sion was determined by Western blot analysis
as described in the Methods section.
CYP450 enzymes metabolize arachidonic acid to physio-
logically active substances, the hydroxyeicosatetraenoic
acids (HETEs) and eicosatetraenoic acids (EETs) [13].
The primary arachidonic acid metabolite of CYP450 4A
is 20-HETE [12]. The importance of 20-HETE and other
eicosanoids of CYP450 pathways in renal function is be-
coming increasingly recognized.
Renal tissues, including glomeruli, express CYP450 4A
and synthesize 20-HETE [2–13, 28–30]. Understanding of
intracellular events elicited by 20-HETE is incomplete.
20-HETE has been shown to alter expression of key en-
zymes involved affecting phosphorylation in vasculature
[13]. 20-HETE also alters phosphorylation pathways in
renal tubules [13]. Responses of glomeruli and glomeru-
lar cells to 20-HETE have not been described previously.
Several studies suggest that CYP450 4A and 20-HETE
are involved in PAN nephrosis and other proteinuric rat
models [31]. Fibrates, cyclosporine A, corticosteroids, or
ACE inhibitors, drugs that increase CYP450 4A expres-
sion, prevent or reduce proteinuria in PAN nephrosis
[32–35]. Furthermore, glomerular CYP450 content was
undetectable in rats with PAN nephrosis [17], while treat-
ment that preserved enzyme levels protected from pro-
teinuria in vivo and glomerular epithelial cell toxicity in
vitro [17]. These investigators postulate that PAN inter-
acts with CYP450 2B in glomerular epithelial cells, caus-
ing the generation of ROS that then degrade the enzyme
itself [18]. This, in turn, leads to the release of free iron
contained in the heme moiety of the enzyme and to fur-
ther formation of injurious ROS. Hoagland, Maier, and
Roman [36] demonstrated that superoxide inhibits 20-
HETE production by renal cortical microsomes and en-
hances degradation of 20-HETE, while an superoxide
dismutase (SOD) mimetic increases 20-HETE urinary
excretion and reduces proteinuria and glomerulosclero-
sis in a proteinuric rat model. Whether ROS generated
as a result of PAN treatment affect levels of CYP450 4A
and/or 20-HETE remains to be determined.
Numerous interactions among enzymes and
eicosanoids complicate interpretation of studies of
physiologic responses to pharmacologic interventions.
20-HETE is metabolized by cyclooxygenase to phys-
iologically active metabolites; likewise, products of
cyclooxygenase are substrates for CYP450 4A [12,
13, 37]. Fibrates increase and decrease the expression
of other enzymes, such as CYP450 2B and CYP450
4F, respectively [9, 38]. Thus, maneuvers that alter
CYP450 expression and/or activity can alter subsequent
metabolism of various eicosanoids. Studies are currently
underway in our laboratory to examine the effect
of alternative eicosanoids and further metabolized
products.
The mechanism by which 20-HETE protects the
glomerular protein permeability barrier is not clear. Se-
lectivity of the permeability barrier is contingent upon the
structural and functional integrity of several key podocyte
proteins, including nephrin, podocin, and other newly de-
scribed components [39]. It is possible that 20-HETE or
its metabolites enhance the function of one or more of
these structural components. 20-HETE activates protein
kinase C, mitogen-activated protein kinase, and other
kinases in some cell lines [21, 40], and could alter the
phosphorylation state of critical podocyte proteins, nor-
malizing or enhancing barrier function. Alternatively,
20-HETE may affect other key mediators, such as nitric
oxide or ROS, which in turn change podocyte function.
Previous studies from our laboratory show that ROS [41,
42] or protein phosphorylation [43] can alter the glomeru-
lar filtration barrier.
CONCLUSION
We demonstrate that PAN has an immediate effect on
the permeability barrier of isolated glomeruli. We report
for the first time that exogenous 20-HETE has direct
and protective effect on the protein permeability barrier.
Furthermore, our results that glomeruli from clofibrate-
treated rats are protected from PAN-induced increase in
Palb and have increased levels of CYP450 4A are consis-
tent with glomerular generation of a protective CYP450
metabolite such as 20-HETE. These results provide ratio-
nale for an in vivo role for fibrates or related compounds
with potential for protection in glomerular injury. Our
findings may be widely applicable, in that relative lack of
20-HETE may be a general characteristic of proteinuric
states. Conversely, measures used to treat and/or prevent
proteinuria may act to restore or increase glomerular 20-
HETE levels. Our findings shed light on current clinical
experience in the empiric treatment of proteinuria, and
pave the way to development of measures to prevent and
treat proteinuria by modulation of CYP450 4A pathway
or by use of analogues of 20-HETE.
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